Yeast surface display libraries of human IgG1 Fc regions were prepared in which loop sequences at the C-terminal tip of the CH3 domain were randomized. A high percentage of these library members bound to soluble CD64 and Protein A indicating that the randomization step did not grossly interfere with the overall structure of the displayed Fc. Sorting these libraries by FACS for binders against HER2/neu yielded antigen-specific Fc binders (Fcab; Fc antigen binding) of which one was affinity matured, resulting in Fcab clone H10-03-6 which showed >10-fold improvement in antigen-binding activity versus the parental clone. Pre-equilibrium surface plasmon resonance experiments revealed a K D value of 69 nM. H10-03-6 did not react with other members of the HER family and specifically interacted with HER2-positive but not with HER2-negative cells. Importantly, Fcab H10-03-6 elicited potent antibody-dependent cellular cytotoxicity in vitro. Finally, the in vivo half-life in mice was similar to wild-type Fc indicating that the amino acid changes in the CH3 domain did not affect the pharmacokinetic behavior of the recombinant Fc. Our data demonstrate that the Fcab scaffold combines all features of normal antibodies in a small 50 kD homodimeric protein: antigen binding, effector functions and long half-life in vivo.
Introduction
Stimulated by the success of therapeutic antibodies (Reichert, 2008) , a variety of antibody fragments and alternative scaffold proteins have been developed that can be engineered to bind specifically to theoretically any target molecule (Wurch et al., 2008) . The small size of such fragments offers the advantage of potentially improved tissue penetration as well as production benefits. However, for therapeutic applications, alternative binders generally suffer from shortcomings, like their inability to elicit effector functions, as well as a limited in vivo half-life. Protein engineering and chemical derivatization strategies to overcome these limitations exist (Werle and Bernkop-Schnurch, 2006 ) but usually outweigh the advantages offered by small fragments. These limitations are likely the main reasons why still today antibody fragments and alternative binding scaffolds are by far less likely to reach the clinic than complete antibodies (Nelson and Reichert, 2009 ).
An immunoglobulin molecule can be dissected into its Fab arms and into the Fc fragment. The Fab fragment encompasses the variable domains as well as one constant domain of each light and heavy chain and carries the antigen-binding site characteristic and unique to each antibody. The Fc fragment is a homodimer made up of two heavy chain constant region parts and contains a number of generic binding sites that are common to all members of the same immunoglobulin class. IgG1 Fc, for example, can interact with Fc gamma receptors I, II and III (CD64, CD32 and CD16, respectively), which mediate effector functions such as antibody-dependent cellular cytotoxicity (ADCC). In addition, binding sites for the complement activator C1q as well as for the neonatal Fc receptor (FcRn) are present. Fc binding to FcRn is responsible for the long half-life of antibodies (Jefferis and Lund, 2002) . Isolated Fc regions, mostly in the form of fusion proteins, have been shown to retain all these functions even in the absence of Fab arms (Zheng et al., 1999; Powers et al., 2001) .
Immunoglobulin domains evolved an outstanding capacity to tolerate variability in loop lengths and sequences while maintaining their overall structure and function. This is most evident for the CDR regions of variable domains of antibodies, but is generally observed in protein domains belonging to the immunoglobulin fold family (Halaby et al., 1999) . Not only natural variation in loops can be tolerated in immunoglobulin domains, but also artificially introduced sequences. Using large libraries with randomized loop sequences, specific binders can be efficiently evolved, as has been shown, for example, with the 10th fibronectin type III domain of human fibronectin (Koide et al., 1998; Olson and Roberts, 2007) . Recently, the CH2 domain of human IgG1 has been used as a library scaffold, and isolated CH2 domains with specific binding affinity to a HIV-1 gp120-CD4 complex have been described. There, the new binding site is formed by engineered sequences in the BC and FG loops of the CH2 domain (Xiao et al., 2009 ), located at the N-terminal tip of † These authors contributed equally to the work. the domain. However, isolated CH2 domains with mutations in these loops are unlikely to be able to elicit effector functions, since binding of the Fc fragment to Fc gamma receptors occurs in an asymmetric fashion in the lower hinge region and in the upper CH2 region and involves different residues from each of the chains of the Fc, including CH2 loop residues.
We show here that the Fc fragment of IgG1 is an ideal alternative small-size antibody format. With the exception of an antigen-binding site, it has all the attractive properties of a complete antibody, i.e. the ability to elicit effector functions via binding to Fc-gamma receptors and to the complement activator C1q, as well as the long half-life of antibodies mediated through binding to FcRn (Jefferis and Lund, 2002) . The loop regions, which are ideally suited for the generation of antigen-binding sites, are the ones located at the C-terminal tip of the CH3 domain and include loops AB, CD and EF (Kaas et al., 2007) . Although both the AB and the EF loops are not unordered loops in the strict sense, but contain short a-helical stretches, we show here that the protein sequence space available to replace them while retaining the crucial characteristics of the Fc is large enough in order to allow for the formation of binding sites to new antigens. We have created a large yeast display library of engineered Fc fragments, containing randomized positions and insertions in the AB and in the EF loops, and have isolated Fc fragments which bind specifically and with high affinity to HER2/neu. Such Fc fragments are termed 'Fcab', i.e. Fc antigen binding (Fcab is a trademark of f-star Biotechnologische Forschungs-und Entwicklungsges.m.b.H.). One of these Fcabs, H10-03-6, elicits ADCC in vitro and has an in vivo half-life in mice similar to wild-type Fc.
Materials and methods

Library design, construction, cloning and display
The pYD1 yeast display vector kit was used (Invitrogen, Carlsbad, CA, USA). The vector pYD1 was modified to remove the XhoI restriction site in the multiple cloning site to yield the construct pYD1dX.
The sequence of wild-type human Fc encompassing the hinge region as well as CH2 and CH3 domains was cloned into the BamHI and NotI sites of pYD1dX to yield pYD1dXFc. To facilitate later exchange of domains, a silent mutation leading to a unique XhoI site near the border between CH2 and CH3 was introduced in the gene encoding the Fc. For cloning the libraries, pYD1dXFc was modified by removing a 225-bp fragment of the CH3 domain between naturally occurring XmaI and NsiI sites in the vector pYD1dXFc and inserting a synthetic oligonucleotide containing two asymmetric BsmBI sites to yield vector pYD1dXFcdel.
Genes encoding the libraries were synthesized by Geneart (Regensburg, Germany). Residues 358 -362, 413-415 and 418-419 (Kabat EU numbering; Kabat et al., 1991) in the CH3 domain were randomized using the codon NNB. An insertion of 5 NNB codons was placed at position 415 (inserted residues are numbered 415a -415e). Sequences required for gap repair driven homologous recombination in yeast were appended to the library genes in a PCR reaction using primers ABNest and NsiNest (for oligonucleotide sequences see Supplementary Material, available at PEDS online). BsmBI linearized vector pYD1dXFcdel and gelpurified library insert were used to transform Saccharomyces cerevisiae EBY100 (Invitrogen) cells using the lithium acetate method (Gietz and Schiestl, 2007) . Growth of the libraries, induction of display and determination of library size were performed according to standard protocols (Invitrogen). Libraries and clones were monitored for display using solutions of 5.4 mg/ml anti-Xpress antibody (Invitrogen) and for the quality of displayed protein using 1:2000 diluted polyclonal phycoerythrin-R conjugated antihuman Fc serum (Sigma, St Luis, MO, USA), 18 mg/ml FITC-conjugated Protein A (Sigma), mouse anti-hIgG1 (anti-CH2)-FITC (AbD Serotec, Düsseldorf, Germany) and 1 mg/ml his-tagged CD64 (R&D Systems, Minneapolis, MN, USA) together with 1 mg/ml anti-His antibody conjugate with Alexafluor 488 (Qiagen, Hilden, Germany).
Library sorting and pool sequence diversification
Yeast were cultured as described (Chao et al., 2006) . Briefly, transformed yeast cultures were inoculated over night at 288C in SD-CAA medium, diluted to OD 600 ¼ 0.5 and continued to grow to OD 600 ¼ 1. Yeast were collected by centrifugation, resuspended in SGR-CAA medium at an OD 600 ¼ 0.1 and cultivated overnight at 208C. For staining, yeast were harvested and resuspended in PBSA [0.01 M sodium phosphate, pH 7.4, 0.137 M sodium chloride, 20 g/l bovine serum albumin (BSA)] for staining and sorting. The first two sorting rounds were conducted with 350 nM HER2/ neu-ECD (Bender MedSystems, Vienna, Austria) which had been biotinylated at a 1:3 ratio. Library selections were performed in PBSA after allowing the binding reaction to equilibrate for at least 1 h at room temperature. Yeast cells were pelleted, washed with ice-cold PBSA and resuspended in PBSA with 10 mg/ml streptavidin-R-phycoerythrin and 2 mg/ ml FITC-labeled Protein A (Sigma). Cells were incubated with secondary reagents for 30 min on ice, washed once with PBSA, resuspended in PBS and sorted on a FACSAria cell sorter (BD, Franklin Lakes, NJ, USA). Setting of sort gates typically allowed 0.1% false-positive cells as judged by control staining in the absence of antigen.
For sorting round 3, the previously selected pool of clones was diversified by completely re-randomizing the AB loop sequence. Plasmids from clones selected after two rounds of sorting of the naïve library were isolated from 10 8 yeast cells using a Zymoprep II kit (Zymo Research, Orange, CA, USA) according to the manufacturers' instructions, except for an extended centrifugation of the neutralized precipitate. This DNA was used as PCR template with the degenerated primer AB þ 2LRmut, randomizing residues 358-362 in the AB loop and primer NsiNest which primes downstream of the EF loop. Gel-purified PCR products together with the BsmBI-linearized vector pYD1dXFcdel were transformed into S. cerevisiae EBY100, resulting in a library of 3.2 Â 10 7 independent clones. Selection of the resulting yeast library was performed as described above, with a labeling concentration of HER2/neu-ECD of 118 nM in round 3 and 29 nM in round 4. Thirteen selected clones were expressed in soluble form and characterized for binding to HER2/ neu-ECD. Clone H242-9 was chosen from this group for affinity maturation.
Affinity maturation
An affinity maturation library of clone H242-9 was constructed by PCR, performing complete re-randomization of the AB loop and parsimonious mutagenesis (Balint and Larrick, 1993) of residues 413-419 in the EF loop. For the AB loop, primer AB þ 2LRmut was used as above as a 5 0 -primer. As a 3 0 -primer, the partially degenerate primer H242-9EFspike was designed as follows: at the first two positions of each codon, the sequence contained 70% of the original nucleotide and 10% each of the other three nucleotides. At the third base of each codon, 70% of the original nucleotide and 30% of the corresponding nucleotide (according to the degenerate codon NNK or NNS, respectively) was used. Purified PCR product was re-amplified using AB þ 2LRmut as a 5 0 -primer as above and NsiNest as a 3 0 -primer to append the site for gap repair cloning of the CH3 domain into pYD1dXFcdel. Transformation of the libraries to S. cerevisiae EBY100 yielded a library size of 1.0 Â 10 7 .
Culturing and three rounds of sorting were performed as described above with a labeling concentration of HER2/ neu-ECD of 10 nM. Screening revealed one dominating clone, designated H10-03-6, which was subsequently characterized in detail.
Expression and purification of Fcabs
All Fcabs were cloned in frame with an N-terminal human Vk signal peptide (Felgenhauer et al., 1990) for secretion in the mammalian expression vector pCEP4 (Invitrogen). HEK293 freestyle cells (Invitrogen) were transiently transfected using the MAX reagent (Invitrogen) according to the manufacturers' protocols. After 5 days, the supernatant was harvested and purified over a Protein A HP column (GE Healthcare Bio-Sciences AB, Uppsala, Sweden) according to manufacturers' instructions.
Antigen-specific ELISA and BIAcore HER2/neu-ECD was obtained from Bender MedSystems. Soluble EGFR was purified from the supernatant of A431 cells using a Cetuximab (Merck) affinity column, and HER3 and HER4 were obtained from R&D Systems as Fc-fusion proteins. sEGFR and HER2/ECD were immobilized on Maxisorp plates (Nunc A/S, Roskilde, Denmark) at 2 mg/ml in PBS over night at 48C. Purified Fcabs were applied to coated wells for 90 min at room temperature. After extensive washing, binding was detected with an anti-CH2 antibodyhorseradish peroxidase conjugate (AbD Serotec) and revealed with TMB substrate (Sigma). Binding to HER3 and HER4 was measured in a slightly different way. The target proteins were immobilized at 0.5 mg/ml and biotinylated Fcabs were added as above. Bound Fcabs were detected with a streptavidin-horseradish peroxidase conjugate (GE Healthcare Bio-Sciences AB).
Surface plasmon resonance was measured using a BIAcore 3000 instrument (GE Healthcare Bio-Sciences AB). The running buffer was 0.01 M HEPES, pH 7.4, 150 mM NaCl, 3 mM EDTA and 0.005% surfactant P20. A fixed amount of Fcab (28 nM) was incubated with increasing concentrations of HER2/neu-ECD for 10 min at room temperature. Then, the mixtures were applied on a CM5 chip on which 1000 RU of HER2/neu-ECD had been immobilized. The concentration of free Fcab was determined based on an H10-03-6 standard curve. Alternatively, varying concentrations (14.2-113.6 nM) of H10-03-6 were injected onto a CM5 chip coated with 1000 RU of HER2/neu-ECD. The interaction was measured at a flow of 10 ml/min with 3 min injection of H10-03-6 and an off-rate measurement of 2.5 min with buffer flow. The signal of an uncoated reference cell was subtracted from the measurements. The K D values of the interaction were calculated with a 1:1 fit using BIAevaluation 3.2 (BIAcore).
FACS staining of human breast cancer cell lines
Breast cancer lines were obtained from ATCC. MDA-MB468 cells were cultured in Iscove's modified Dulbecco's medium containing 10% fetal calf serum and 8 mM glutamine. SKBR-3 and Calu-3 cells were cultured in RPMI1640 containing 10% fetal calf serum and 8 mM glutamine. The cells were harvested by trypsinization. A total of 1 Â 10 5 cells in PBS containing 0.1% BSA were incubated with Fcab dilutions starting from 5 mg/ml and incubated on ice for 60 min. After removal of excess Fcab, cells were incubated for 60 min with phycoerythrin-R-coupled polyclonal antihuman Fc antibody (Sigma). Measurements were performed on a Becton Dickinson FACSCalibur cytometer.
Antibody-dependent cellular cytotoxicity
Fresh primary human NK cells were isolated from PBMCs by negative selection using magnetic beads (NK isolation kit, Miltenyi Biotec, Germany) in an AutoMACS instrument. A total of 5 Â 10 5 NK cells were mixed with 1 Â 10 5 Calu-3 cells which had been pre-incubated with graded concentrations of Fcab protein for 20 min at 378C. After 4 h at 378C, 7-AAD (Sigma) was added and the percentage of 7-AAD positive cells was determined by flow cytometry.
Pharmacokinetics
The in-life part of the mouse pharmacokinetic study was performed by the Austrian Research Centers GmbH, Seibersdorf. A single intravenous injection of 10 mg/kg purified Fcab was administered into the tail vein of BALB/c mice. Blood samples were taken from the retro-orbital plexus using hematocrit capillary tubes before and several time points after injection. Human IgG1 Fc in the sera was measured by two different ELISA protocols. Briefly, F(ab 0 ) 2 fragment directed against human Fc (Sigma) was coated at 1 mg/ml overnight. Serial dilutions of sera were added and incubated for 1 h at room temperature. Bound Fc fragments were detected with Protein A coupled to horseradish peroxidase for 30 min. Alternatively, sera were tested for binding to immobilized HER2/neu ECD as described above.
Results
Library design
A yeast surface display library of Fc fragments was constructed in which residues 358-362 (Kabat EU numbering; Kabat et al., 1991) in the AB loop and 413-415, 418 and 419 in the EF loop were randomized using the codon NNB. In addition, five random codons were inserted at position 415 in order to increase sequence diversity as well as the size of the newly created interaction surface. The sequence of the CH3 domain library insert and a structural model of a corresponding Fc, which was built using SWISS-MODEL (http://swissmodel.expasy.org//SWISS-MODEL.html; Schwede et al., 2003) , are shown in Fig. 1 .
Library display
Yeast display of the Fc library and of isolated clones was performed on the surface of S. cerevisiae using standard methods, employing the system where a host cell-encoded copy of the Aga1 protein is linked via disulfide bridges to a vector-encoded copy of the Aga2 protein, which is fused to the protein to be displayed (Boder and Wittrup, 1997) . The display vector used for this work thus encoded a fusion protein consisting of an N-terminal Aga2 protein followed by an Xpress epitope for normalization, followed by the displayed Fc. No C-terminal tag was attached to the Fc in order to avoid possible interaction with the engineered antigen-binding site. A schematic presentation of the Fc display cassette and of the configuration of the displayed protein on the surface of the yeast is shown in Fig. 2 .
The Fcab displaying library (7.4 Â 10 7 independent yeast transformants) was characterized by FACS analysis for staining with Protein A and with soluble recombinant CD64, in comparison with wild-type Fc displayed in the same system. Staining with an antibody directed against the Xpress epitope was used to estimate the expression level and the fraction of displaying clones. It was found that $34% of the displaying library clones bound to CD64 and $45% bound to Protein A, indicating a large proportion of clones that maintained these crucial binding properties in the presence of engineered AB and EF loops (Fig. 3) .
Library sorting and pool sequence diversification
For the selection of binders to HER2/neu, FACS sorting was performed using biotinylated HER2/neu extracellular domain (HER2/neu-ECD) as target antigen at concentrations decreasing from 350 to 30 nM over successive rounds. After the second sorting round, the sequence diversity in the selected pool was increased by totally re-randomizing the five AB loop positions by PCR. After round 4, 13 clones binding to HER2/neu-ECD, all sharing the same EF loop, were identified, out of which one, designated H242-9, was the best binder and was therefore selected for affinity maturation.
Affinity maturation
Affinity maturation was performed by totally re-randomizing the AB loop residues as above and, in addition, randomizing EF loop residues of clone H242-9 by parsimonious mutagenesis including Arg416 and Trp417, using the spiked Antigen-binding engineered Fc oligonucleotide H242-9EFmut. Three rounds of FACS sorting were performed using 10 nM biotinylated HER2/neu-ECD for labeling, which is a subthreshold concentration for the parent clone. Screening of individual sorted clones revealed one dominating Fcab, designated H10-03-6. The sequences of H242-9 and H10-03-6 are provided in Fig. 1 (sequences of selected AB and EF loops) and in Supplementary Material (complete sequences, available at PEDS online). Both clones were found by FACS analysis to stain well with Protein A, soluble CD64 and a monoclonal antibody against the CH2 domain, indicating their structural integrity (Fig. 4a) . Binding of the yeast-displayed Fcabs to biotinylated HER2/neu-ECD was shown by FACS analysis (Fig. 4b) and was found to be concentration dependent (Fig. S1 , Supplementary data are available at PEDS online). Improved binding of clone H10-03-6 relative to the parent clone can be seen.
Expression and purification of Fcabs
Fcabs were produced in soluble form by transient expression in HEK293 cells. After purification by Protein A affinity chromatography, SDS-PAGE revealed bands of the expected size and of high purity (Fig. 5) . This type of expression and purification setup consistently gave production yields of 3 -6 mg/l depending on the Fcab clone.
Specific binding to HER2/neu
Binding to immobilized HER2/neu-ECD was measured in an ELISA, resulting in a half maximal signal at 66 nM for H242-9, whereas the matured clone H10-03-6 showed a half maximal EC 50 at 4.4 nM (Fig. 6a) . The affinity of H10-03-6 for its target was determined by surface plasmon resonance. In a first set of experiments, a fixed amount of H10-03-6 was mixed with different concentrations of HER2/neu in solution followed by determination of unbound Fcab. In these preequilibrium assays, a K D value of 69 nM was determined for H10-03-6 binding to HER2/neu-ECD (Fig. 6b) . In another set of experiments binding of graded amounts of H10-03-6 to HER2/neu immobilized on a BIACore chip resulted in a higher affinity with a K D value of 8.6 nM (see Fig. S2 , Supplementary data are available at PEDS online). The higher affinity in this experimental setup compared with the pre-equilibrium measurements is likely due to contribution of avidity effects.
The extracellular domains of the members of the ErbB family are structurally homologous. The protein sequence of HER2/neu shares between 48% and 50% identity with that of EGFR, HER3 and HER4. We investigated the cross reactivity of H10-03-6 against EGFR, HER3 and HER4 in ELISA. H10-03-6 did not bind to any of these proteins (see Fig. S3 , Supplementary data are available at PEDS online).
To check whether the selected Fcabs would also recognize their cognate antigen on a cell surface, the HER2/neu positive cell line SKBR3 and the HER2/neu negative cell line MDA-MB468 were used. Fcab H10-03-6 reacted with SKBR3 cells in a dose-dependent fashion, whereas H242-9 was considerably weaker indicating the superiority of H10-03-6 also on the cellular level. In contrast, no binding of H10-03-6 to MDA-MB468 cells was observed supporting the antigen specificity data in the ELISA (Fig. 6c) .
Antibody-dependent cellular cytotoxicity
ADCC is considered a major mechanism by which therapeutic antibodies mediate their clinical efficacy. Therefore, it was important to determine if also an Fcab was able to support this effector function. ADCC was tested in vitro using freshly isolated primary human NK cells as effector cells and Calu-3 cells as target cells. Calu-3 cells express high levels of HER2/ neu and bind H10-03-6 similar to SKBR3 cells. Interestingly, 
Antigen-binding engineered Fc
H10-03-6 was able to kill Calu-3 cells in a dose-dependent fashion with an EC 50 of 0.6 nM (Fig. 6e) . H10-03-6 did not lead to cell death in the absence of effector NK cells indicating the killing mechanism was due to ADCC and not due to a direct effect of the Fcab on the target cells (see Fig. S4 , Supplementary data are available at PEDS online). As positive control, the anti-HER2/neu monoclonal antibody Herceptin was tested in parallel. This antibody killed Calu-3 cells with an EC 50 of 0.02 nM indicating that the ADCC potency of H10-03-6 was $20-fold weaker.
Pharmacokinetics
To determine if the amino acid changes in the CH3 domain of Fcab H10-03-6 would affect its half-life in vivo, the elimination (b-phase) half-life was assessed after i.v. injection of H10-03-6 or wild-type Fc in BALB/c mice. The calculated t 1/2b of wild-type Fc and H10-03-6 was 40.2 and 85.6 h, respectively, which is similar to previously reported data of human Fc in rodents (Kim et al., 1999) . Importantly, the same t 1/2b was calculated when the mouse sera were tested for HER2/neu binding indicating that the protein remained fully functional during the observation period (see Fig. S5 , Supplementary data are available at PEDS online). Overall, these results indicated that the mutations introduced in the CH3 domain to form the HER2/neu-binding site did not adversely affect the pharmacokinetic properties of the Fcab molecule (Fig. 6e) .
Discussion
In this study, we demonstrate that Fc fragments can be functionalized to form antigen-binding sites by engineering structural loops in the CH3 domains. These loops, located at the C-terminal tip of the Fc fragment, are otherwise not involved in forming binding sites either for effector molecules like Fc gamma receptors or factors of the complement system or for the FcRn, the binding of which endows antibodies with their long in vivo half-life. The regions chosen by us for randomization and selection are located in the EF and in the AB loops, respectively. Both these loops contain short a-helical stretches, and although they are thus not loops in the strict sense, their replacement by random sequence has allowed us to establish libraries from which stably folding and well expressing Fc mutants with engineered binding sites could be selected with high efficiency. The choice of positions for randomization was based on the following criteria: their side chains should be well exposed to the solvent and they should be as structurally independent as possible from the body of the Fc fragment; furthermore, the individual surfaces of the two loops together should form a coherent surface patch on the tip of the CH3 domain, creating the complete engineered binding site. Our choice was to use positions 358-362 in the AB loop, and 413-415 as well as 418-419 in the EF loop. We deliberately did not randomize Arg416 because it forms an important salt bridge with Glu388, and Trp417 was left unchanged because its side chain is almost completely buried in the molecule, as judged from the observation of crystal structures of Fc fragments (PDB files 1OQO and 1HZH). In addition to randomizing these 10 positions, five residues were inserted in the N-terminal part of the EF loop, in order to increase the available sequence and structure space in the library, in a manner similar to the natural occurrence of CDR loop elongations in antibodies. Although we restricted the randomized positions and the number of insertions to this single format, we anticipate that it may prove useful for the fine-tuning of selected clones as well as for the design of future libraries to use a more diverse set of loop architectures both in terms of choice of randomized positions as well as loop lengths and sites of loop elongation. In addition, the CD loop as the third available loop next to AB and EF loop could also be a target for randomization and elongation.
We decided to use the yeast S. cerevisiae for displaying the library due to the fact that the Fc fragment is a glycoprotein, which naturally forms a disulfide-linked homodimer. Therefore, it was expected that a eukaryotic display system might be better suited than e.g. phage display in Escherichia coli. Supporting this concept, the library contained a high percentage of CD64 positive clones as revealed by FACS staining using recombinant CD64, indicating that the Fc fragments were in fact functionally displayed as glycosylated homodimers on the yeast surface. Positive staining of a large proportion of the library with Protein A was another indicator that the Fc scaffold tolerated well the modification of its structural loops in the CH3 domain and that S. cerevisiae was an efficient host for expression and display of the engineered Fc fragments.
Engineering antigen-binding sites into Fc fragments opens the route to miniaturized antibody-like molecules, since the Fc is carrying all effector molecule-binding sites as well as the binding site for FcRn that together make up the complete functionality of immunoglobulins. Of course, this necessitates that these binding sites are functionally preserved and unimpaired by the engineering of the structural loops of the CH3 domain. Using clone H10-03-6, we have been able to demonstrate this by showing that it not only binds to HER2/ neu-ECD with high affinity, but that it also elicits ADCC in vitro and that it has an in vivo half-life in mice comparable to that of wild-type Fc.
A number of non-antibody scaffolds have been developed recently that may have the potential to at least partially replace classical monoclonal antibodies in different fields of application (Kolmar and Skerra, 2008) . For example, DARPins binding specifically to HER2 with picomolar affinities have been reported to be useful for targeted therapy and tumor imaging applications (Zahnd et al., 2007 ). An affibody with 27 pM affinity to HER2 was shown to be efficient in radionuclide targeting to HER2 positive tumor cells in mice (Ahlgren et al., 2009) . These so-called alternative scaffold binding proteins offer practical benefits such as robustness, small size and ease of expression. However, since they usually have short in vivo half-lives and furthermore do not display effector functions, their general therapeutic use is rather limited when compared with the engineered Fcabs described here. At a size of 52 kD, an Fcab has all the properties of a full size antibody: antigen binding, effector functions and long half-life. To our knowledge, this is the only type of antibody fragment or alternative protein scaffold known to date that combines all these properties in one molecule without further engineering or derivatization. It is therefore a prototype for a new generation of fully functional antibody fragments.
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